Rosiglitazone Recall

On July 30, 2007 the US government began to look into the safety concerns about the diabetes treat drug Avandia (rosiglitazone), with a top safety scientist urging a rosiglitazone recall from the market. David Graham, a safety scientist with the Food and Drug Administration, informed FDA advisors that the drug appears to increase the risk of a heart attack in certain patients. The Avandia Lawyer of Ennis & Ennis, PA, suggests that people who have experienced, or have loved ones who have experienced a heart attack, stroke or congestive heart failure after using avandia or rosiglitazone treatment should contact the Avandia Lawyer as they may be entitled to compensation.

The rosiglitazone recall was suggested in 2007, but is still on the market as a treatment for diabetes sufferers. Ennis & Ennis is a national mass tort law firm with offices in Washington DC and Florida (Miami & Ft. Lauderdale). Ennis & Ennis works with law firms nationwide to provide clients with the best possible representation to protect their legal rights and maximize their remedies under the law. The Avandia Lawyer informs that when Graham urged a rosiglitazone recall, he cited research to make his argument that there is no evidence of major health benefits from taking the drug, and that leaving it on the market may "cost thousands of lives."

The rosiglitazone recall was supported by the study in the New England Journal of Medicine which linked Avandia/rosiglitazone with a 43 percent higher risk of heart attacks. The Avandia Lawyer invites people who have lost a close friend or family member after using the treatment to call and make inquiries and give details. The Avandia Lawyer of Ennis & Ennis has a team of professionals dedicated to helping clients deal with all aspects of an Avandia/rosiglitazone claim will help to get them a fair settlement or verdict in an efficient and expeditious manner. Each claim will support the rosiglitazone recall suggestion and help save the lives of other patients. GlaxoSmithKlein, the maker of Avandia/rosiglitazone, disputed Graham's findings and rejected his rosiglitazone recall plea.

The company said many studies have already been conducted, involving thousands of subjects, and that "there is no consistent or systematic evidence that Avandia increases the risk of heart attacks or death from cardiovascular disease compared to other drugs." The Avandia Lawyer is empathetic but forceful, and will uncover justice for each unique case through every step of the legal process. After Graham's rosiglitazone recall advice, government safety scientists advised the FDA that Avandia/rosiglitazone should not be used in combination with insulin or by patients with heart disease.

The Avandia Lawyer is aware that since the drug Avandia/rosiglitazone was approved, FDA stated that it has updated the product's labeling on several occasions to reflect new data, the most recent being 2006, which included a new warning about a potential increase in heart attacks and heart-related chest pain in some individuals using Avandia, which was based on the result of a controlled clinical trial in patients with existing congestive heart failure. The Avandia Lawyer informs that the rosiglitazone recall was made in 2007 and the drug is still on the market.